The European Orphan Regulation has transformed the landscape for rare disease research over the past two decades, helping to stimulate the development of treatments for patients with conditions that were previously overlooked by traditional pharmaceutical investment models. Yet as policymakers continue to evaluate the Regulation and consider future reforms, one fundamental question remains: how much has the legislation really contributed to innovation?

This report examines that question through an economic lens, using a risk-adjusted net present value (rNPV) model to explore how regulatory incentives influence investment decisions in orphan medicines. Rather than relying solely on historical approval trends, the analysis considers the commercial realities that shape whether companies choose to invest in developing treatments for rare diseases. 

The findings challenge several assumptions that have shaped recent policy discussions. The report suggests that a significant proportion of orphan medicines developed since the introduction of the Regulation may not have been economically viable without the incentives it provides. It also highlights that, despite these incentives, developing orphan medicines remains a financially marginal proposition, underlining the continued importance of maintaining a policy environment that encourages investment while supporting patient access. 

As Europe considers reforms to its pharmaceutical legislation, understanding the relationship between incentives, investment and innovation has never been more important. Decisions made today will influence the future pipeline of therapies for thousands of rare diseases that still have no approved treatment.